Photon-counting detector CT (PCD-CT) represents a transformative advancement in CT technology, overcoming limitations of conventional energy-integrating detector (EID) based systems. It uses semiconductor materials such as cadmium telluride, cadmium zinc telluride, and silicon to directly count X-ray photons while resolving their energy levels. This energy-resolving capability ensures equal weighting of low- and high-energy photons, eliminates electronic noise, and enables material-specific imaging. The absence of physical septa in the detector—used in EIDs to prevent light photon cross-talk—results in smaller effective detector pixels in PCD-CT, enhancing detection efficiency and spatial resolution. These innovations collectively enhance diagnostic accuracy while enabling significant radiation dose reduction. This article provides a comprehensive overview of PCD-CT technology, comparing it with EID-based systems. It highlights key advantages such as superior spatial and contrast resolution, spectral imaging, and noise reduction. Additionally, the review discusses PCD-CT’s radiation dose reduction across cardiovascular, thoracic, abdominal, musculoskeletal, neuroimaging, and paediatric applications. Despite its promise, PCD-CT faces challenges, including non-ideal detector performance, increased electronic complexity, and calibration requirements to maintain accuracy. Addressing these issues will be crucial for widespread clinical adoption. As research progresses and technology improves, PCD-CT is expected to reshape clinical practice by integrating high diagnostic accuracy with improved radiation efficiency.
Understanding the unique features of photon-counting CT and being familiar with terminology and setup processes are essential to effectively implement this modality in clinical practice.
Simultaneous dual-contrast imaging of iodine and bismuth has shown promise in prior phantom and animal studies utilizing spectral CT. However, it is noted that in previous studies, Pepto-Bismol has frequently been employed as the source of bismuth, exceeding the recommended levels for human subjects. This investigation sought to assess the feasibility of visually differentiating and precisely quantifying low-concentration bismuth using clinical dual-source photon-counting CT (PCCT) in a scenario involving both iodinated and bismuth-based contrast materials. Four bismuth samples (0.6, 1.3, 2.5, and 5.1 mg/mL) were prepared using Pepto-Bismol, alongside three iodine rods (1, 2, and 5 mg/mL), inserted into multi-energy CT phantoms with three different sizes, and scanned on a PCCT system at three tube potentials (120, 140, and Sn140 kV). A generic image-based three-material decomposition method generated iodine and bismuth maps, with mean mass concentrations and noise levels measured. The root-mean-square errors for iodine and bismuth determined the optimal tube potential. The tube potential of 140 kV demonstrated optimal quantification performance when both iodine and bismuth were considered. Distinct differentiation of iodine rods with all three concentrations and bismuth samples with mass concentrations ≥ 1.3 mg/mL was observed across all phantom sizes at the optimal kV setting.
We present a case of an 81-year-old woman who presented to the emergency department with bleeding from a right breast wound. The patient had prior imaging suggestive of bilateral silicone implant rupture and a history of low tolerance for MRI scans. Ultrasound imaging in the emergency setting showed findings in the right breast suggestive of a fistula with free silicone and hematoma. A subsequent photon-counting CT scan with custom silicone-specific segmentation allowed differentiation of silicone from hematoma, provided anatomic assessment and location of the fistula, and revealed bilateral silicone-induced lymphadenopathy.